Meta H M Diekstra1, Jesse J Swen1, Epie Boven2, Daniel Castellano3, Hans Gelderblom4, Ron H J Mathijssen5, Cristina Rodríguez-Antona6, Jesus García-Donas7, Brian I Rini8, Henk-Jan Guchelaar9. 1. Department of Clinical Pharmacy and Toxicology, Leiden University Medical Centre, Leiden, The Netherlands; Dutch working group focusing on sunitinib-induced toxicity (SUTOX consortium), The Netherlands. 2. Dutch working group focusing on sunitinib-induced toxicity (SUTOX consortium), The Netherlands; Department of Medical Oncology, VU University Medical Centre, Amsterdam, The Netherlands. 3. Oncology Department, Hospital Universitario 12 de Octubre, Madrid, Spain; Spanish Oncology Genitourinary Group (SOGUG), Madrid, Spain. 4. Dutch working group focusing on sunitinib-induced toxicity (SUTOX consortium), The Netherlands; Department of Clinical Oncology, Leiden University Medical Centre, Leiden, The Netherlands. 5. Dutch working group focusing on sunitinib-induced toxicity (SUTOX consortium), The Netherlands; Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands. 6. Hereditary Endocrine Cancer Group, Spanish National Cancer Research Centre (CNIO), Madrid, Spain; ISCIII Centre for Biomedical Research on Rare Diseases (CIBERER), Madrid, Spain. 7. Spanish Oncology Genitourinary Group (SOGUG), Madrid, Spain; Oncology Unit, Clara Campal Comprehensive Cancer Centre, Madrid, Spain. 8. Department of Solid Tumour Oncology, Cleveland Clinic Foundation (CCF) Taussig Cancer Institute, Cleveland, OH, USA. 9. Department of Clinical Pharmacy and Toxicology, Leiden University Medical Centre, Leiden, The Netherlands; Dutch working group focusing on sunitinib-induced toxicity (SUTOX consortium), The Netherlands. Electronic address: H.J.Guchelaar@lumc.nl.
Abstract
BACKGROUND: In our exploratory studies, we associated single nucleotide polymorphisms (SNPs) in candidate genes with the efficacy and toxicities of sunitinib in metastatic renal cell carcinoma (mRCC). OBJECTIVE: To see whether previously reported associations of SNPs with sunitinib-induced toxicities and efficacy in mRCC can be confirmed in a large cohort of patients. DESIGN, SETTING, AND PARTICIPANTS: The mRCC patients treated with sunitinib and a DNA sample available were pooled from three exploratory studies conducted in the United States, Spain, and the Netherlands. A total of 22 SNPs and 6 haplotypes in 10 candidate genes related to the pharmacokinetics and pharmacodynamics of sunitinib were selected for association testing. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: SNPs and haplotypes were tested for associations with toxicity, dose reductions, progression-free survival (PFS), overall survival (OS), and best objective response. RESULTS AND LIMITATIONS: A total of 333 patients were included. We confirmed 2 of the 22 previously reported SNP associations. The presence of CYP3A5*1 was associated with dose reductions (odds ratio: 2.0; 95% confidence interval [CI], 1.0-4.0, p=0.039). The presence of CGT in the ABCB1 haplotype was associated with an increased PFS (hazard ratio: 1.9; 95% CI, 1.3-2.6; p<0.001) and remained significant after Bonferroni correction. These associations are consistent with prior observations. CONCLUSIONS: The confirmation of previously reported associations between polymorphisms in CYP3A5 and ABCB1 with sunitinib toxicity and efficacy, respectively, indicates that genotyping of these genetic variants will be useful for guiding sunitinib treatment. A prospective validation study is needed to confirm our findings on ABCB1 and CYP3A5 genetic polymorphisms. PATIENT SUMMARY: We confirmed that variants in genes involved in processing sunitinib through the body have an effect on sunitinib treatment outcome. These findings confirm the potential of testing for these genetic variants to improve individual patient care for patients with metastatic renal cell carcinoma treated with sunitinib.
BACKGROUND: In our exploratory studies, we associated single nucleotide polymorphisms (SNPs) in candidate genes with the efficacy and toxicities of sunitinib in metastatic renal cell carcinoma (mRCC). OBJECTIVE: To see whether previously reported associations of SNPs with sunitinib-induced toxicities and efficacy in mRCC can be confirmed in a large cohort of patients. DESIGN, SETTING, AND PARTICIPANTS: The mRCC patients treated with sunitinib and a DNA sample available were pooled from three exploratory studies conducted in the United States, Spain, and the Netherlands. A total of 22 SNPs and 6 haplotypes in 10 candidate genes related to the pharmacokinetics and pharmacodynamics of sunitinib were selected for association testing. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: SNPs and haplotypes were tested for associations with toxicity, dose reductions, progression-free survival (PFS), overall survival (OS), and best objective response. RESULTS AND LIMITATIONS: A total of 333 patients were included. We confirmed 2 of the 22 previously reported SNP associations. The presence of CYP3A5*1 was associated with dose reductions (odds ratio: 2.0; 95% confidence interval [CI], 1.0-4.0, p=0.039). The presence of CGT in the ABCB1 haplotype was associated with an increased PFS (hazard ratio: 1.9; 95% CI, 1.3-2.6; p<0.001) and remained significant after Bonferroni correction. These associations are consistent with prior observations. CONCLUSIONS: The confirmation of previously reported associations between polymorphisms in CYP3A5 and ABCB1 with sunitinibtoxicity and efficacy, respectively, indicates that genotyping of these genetic variants will be useful for guiding sunitinib treatment. A prospective validation study is needed to confirm our findings on ABCB1 and CYP3A5 genetic polymorphisms. PATIENT SUMMARY: We confirmed that variants in genes involved in processing sunitinib through the body have an effect on sunitinib treatment outcome. These findings confirm the potential of testing for these genetic variants to improve individual patient care for patients with metastatic renal cell carcinoma treated with sunitinib.
Authors: Daniel J George; Jean-Francois Martini; Michael Staehler; Robert J Motzer; Ahmed Magheli; Frede Donskov; Bernard Escudier; Sherry Li; Michelle Casey; Olga Valota; Brigitte Laguerre; Allan J Pantuck; Hardev S Pandha; Anup Patel; Maria Lechuga; Alain Ravaud Journal: Clin Cancer Res Date: 2018-11-06 Impact factor: 12.531
Authors: Gracia M Amaya; Rebecca Durandis; David S Bourgeois; James A Perkins; Arsany A Abouda; Kahari J Wines; Mohamed Mohamud; Samuel A Starks; R Nathan Daniels; Klarissa D Jackson Journal: Chem Res Toxicol Date: 2018-06-18 Impact factor: 3.739
Authors: M H Diekstra; A Belaustegui; J J Swen; E Boven; D Castellano; H Gelderblom; R H Mathijssen; J García-Donas; C Rodríguez-Antona; B I Rini; H-J Guchelaar Journal: Pharmacogenomics J Date: 2016-01-26 Impact factor: 3.550
Authors: Guillermo de Velasco; Kathryn P Gray; Lana Hamieh; Yuksel Urun; Hallie A Carol; Andre P Fay; Sabina Signoretti; David J Kwiatkowski; David F McDermott; Matthew Freedman; Mark M Pomerantz; Toni K Choueiri Journal: Eur Urol Focus Date: 2016-04-23